不同培养条件对CD133+原代口腔鳞癌细胞干性维持的影响

doi:10.19439/j.sjos.2022.04.002

上海口腔医学 ›› 2022, Vol. 31 ›› Issue (4): 343-348.doi: 10.19439/j.sjos.2022.04.002

不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响

文旭涛, 马振, 张翀, 陶识丞, 陈兴金, 麦华明

广西医科大学口腔医学院·附属口腔医院广西口腔颌面修复与重建研究自治区级重点实验室,广西颅颌面畸形临床医学研究中心,颌面外科疾病诊治研究重点实验室·广西高校重点实验室,广西南宁 530021

收稿日期:2021-09-06 修回日期:2022-03-08 出版日期:2022-08-25 发布日期:2022-08-30
通讯作者: 麦华明,E-mail：huamingmai@163.com
作者简介:文旭涛（1995-）,男,硕士,E-mail：1084041985@qq.com
基金资助:
国家自然科学基金(81460413)

Maintenance of the stemness in CD133⁺ primary oral squamous cell carcinoma cells under different culture conditions

WEN Xu-tao, MA Zhen, ZHANG Chong, Tao Shi-cheng, CHEN Xing-jin, MAI Hua-ming

College & Hospital of Stomatology, Guangxi Medical University,Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction, Guangxi Clinical Research Center for Craniofacial Deformity, Guangxi Key Laboratory of Oral and Maxillofacial Surgery Disease Treatment. Nanning 530021, Guangxi Zhuang Autonomous Region, China

Received:2021-09-06 Revised:2022-03-08 Online:2022-08-25 Published:2022-08-30

摘要/Abstract

摘要： 目的: 通过将CD133^+/-细胞从原代口腔鳞癌细胞中分离纯化,探索不同培养条件对CD133⁺原代口腔鳞癌细胞的干性维持及生物学特性的影响。方法: 应用CCK-8法检测CD133^+/-细胞亚群体外增殖能力以及对顺铂抵抗耐受能力,利用Transwell法检测顺铂对CD133^+/-细胞亚群侵袭能力的影响。以无血清培养法（含或不含白血病抑制因子LIF）和含血清培养法分别培养CD133⁺细胞亚群,流式细胞仪分析CD133⁺细胞的比例变化。在动物实验模型中验证CD133⁺和CD133^-细胞致瘤能力的差异,最后将移植瘤取出,行H-E染色和免疫组织化学染色。采用SPSS 25.0软件包对数据进行统计学分析。结果: 与CD133^-细胞亚群相比,CD133⁺细胞具备较强的体外增殖能力（P<0.05）和顺铂化疗耐受能力（P<0.001）。顺铂对CD133^-细胞亚群侵袭能力的影响更强（P<0.01）。无血清培养法更能维持CD133的比例（P<0.05）,无血清培养基是否添加LIF对CD133的比例维持无显著差异（P>0.05）。在裸鼠体内成瘤实验中,CD133⁺细胞亚群以较少的数量级表现出较强的致瘤能力（P<0.05）。结论: 无血清培养法可较好地维持原代口腔鳞癌细胞干细胞特性,添加LIF对原代口腔鳞癌细胞的干性维持无显著影响。

关键词: 无血清培养, 白血病抑制因子, 肿瘤干细胞, CD133, 口腔鳞癌

Abstract: PURPOSE: CD133^+/- cells were isolated and purified from primary oral squamous cell carcinoma(OSCC) to explore the effects of different culture conditions on the maintenance and biological characteristics of CD133⁺ primary OSCC. METHODS: CCK-8 was used to detect the ability of proliferation and cisplatin resistance between CD133^+/- cell subsets. Transwell assay was used to compare the invasive ability of two cell subsets under the action of cisplatin. Flow cytometry was used to detect the proportion of CD133⁺ cells cultured by serum free medium(SFM) (with or without leukemia inhibitory factor, LIF) or serum supplied medium (SSM). Subcutaneous tumor model in nude mice was used to verify the difference in tumorigenicity of CD133^+/- cell subsets. The transplanted tumor was removed for H-E staining and immunohistochemistry (IHC). SPSS 25.0 software package was used for statistical analysis. RESULTS: Compared with CD133^- cell subsets, CD133⁺ cell subsets had stronger ability of proliferation in vitro(P<0.05) and cisplatin tolerance(P<0.001). Cisplatin had a stronger effect on the invasive ability of CD133^- cell subsets than CD133⁺ cell subsets (P<0.01). No significant difference in the proportion of CD133⁺ cell between LIF-SFM and no-LIF-SFM was found (P>0.05); but compared with SSM culture method, SFM culture method could maintain the proportion of CD133⁺ cell better(P<0.05). CD133⁺cell subsets showed stronger tumorigenic ability with fewer cells than CD133^- cell subsets in nude mice(P<0.05). CONCLUSIONS: Serum free culture method can better maintain the characteristics of primary OSCC stem cells, but the addition of LIF has no significant effect on the maintenance of stemness of primary OSCC cells.

Key words: Serum free medium method, Leukemia inhibitory factor, Carcinoma stem cells, CD133, Oral squamous cell carcinoma

中图分类号:

R739.8

文旭涛, 马振, 张翀, 陶识丞, 陈兴金, 麦华明. 不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响[J]. 上海口腔医学, 2022, 31(4): 343-348.

WEN Xu-tao, MA Zhen, ZHANG Chong, Tao Shi-cheng, CHEN Xing-jin, MAI Hua-ming. Maintenance of the stemness in CD133⁺ primary oral squamous cell carcinoma cells under different culture conditions[J]. Shanghai Journal of Stomatology, 2022, 31(4): 343-348.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] Kansy K, Mueller AA, Mucke T, et al.A worldwide comparison of the management of surgical treatment of advanced oral cancer[J]. J Craniomaxillofac Surg, 2018, 46(3): 511-520.
[3] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[4] Brennan PA, Subramaniam S, Tsioryannis C, et al.An update on the latest evidence for managing the clinically negative neck (cN0) in oral squamous cell carcinoma[J]. Oral Dis, 2017, 23(3): 287-291.
[5] Li YC, Xu FM, Zhang GQ, et al.Down-regulation of microRNA-21 inhibits cell proliferation and invasion of high-invasion liver cancer stem cells[J]. Eur Rev Med Pharmacol Sci, 2018, 22(22): 7832-7840.
[6] Ishii H, Iwatsuki M, Ieta K, et al.Cancer stem cells and chemoradiation resistance[J]. Cancer Sci, 2008, 99(10): 1871-1877.
[7] Shmelkov SV, St Clair R, Lyden D, et al.AC133/CD133/Prominin-1[J]. Int J Biochem Cell Biol, 2005, 37(4): 715-719.
[8] Wuchter C, Ratei R, Spahn G, et al.Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping[J]. Haematologica, 2001, 86(2): 154-161.
[9] Yin AH, Miraglia S, Zanjani ED, et al.AC133, a novel marker for human hematopoietic stem and progenitor cells[J]. Blood, 1997, 90(12): 5002-5012.
[10] Monzani E, Facchetti F, Galmozzi E, et al.Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential[J]. Eur J Cancer, 2007, 43(5): 935-946.
[11] Aghajani M, Mokhtarzadeh A, Aghebati-Maleki L, et al.CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel[J]. Mol Biol Rep, 2020, 47(5): 3691-3703.
[12] Yin S, Li J, Hu C, et al.CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity[J]. Int J Cancer, 2007, 120(7): 1444-1450.
[13] O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice[J]. Nature, 2007, 445(7123): 106-110.
[14] Alshenawy HA.Significance of expression of cancer stem cell markers CD133 and nestin in pancreatic intraepithelial carcinoma-invasive adenocarcinoma sequence[J]. Appl Immunohistochem Mol Morphol, 2020, 28(3): 205-212.
[15] Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review[J]. Clin Transl Med, 2018, 7(1): 18-31.
[16] Pine AR, Cirigliano SM, Nicholson JG, et al.Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas[J]. Cancer Discov, 2020, 10(7): 964-979.
[17] Figueira Muoio VM, Uno M, Oba-Shinjo S, et al.OTX1 and OTX2 genes in medulloblastoma[J]. World Neurosurg, 2019, 127: e58-e64.
[18] Ma S, Chan KW, Hu L, et al.Identification and characterization of tumorigenic liver cancer stem/progenitor cells[J]. Gastroenterology, 2007, 132(7): 2542-2556.
[19] Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity[J]. Proc Natl Acad Sci USA, 2008, 105(36): 13427-13432.
[20] 房芳. 原代口腔鳞癌细胞中肿瘤干细胞的分离、培养和鉴定 [D]. 南宁: 广西医科大学, 2018.
[21] Yang JP, Liu Y, Zhong W, et al.Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma[J]. Chin Med J (Engl), 2011, 124(7): 1055-1060.
[22] Morrison SJ, Spradling AC.Stem cells and niches: mechanisms that promote stem cell maintenance throughout life[J]. Cell, 2008, 132(4): 598-611.
[23] de Lange T. T-loops and the origin of telomeres[J]. Nat Rev Mol Cell Biol, 2004, 5(4): 323-329.
[24] Longhese MP.DNA damage response at functional and dysfunctional telomeres[J]. Genes Dev, 2008, 22(2): 125-140.
[25] Zhang C, Liu J, Wang J, et al.The emerging role of leukemia inhibitory factor in cancer and therapy[J]. Pharmacol Ther, 2021, 221: 107754.
[26] Fuchs E, Tumbar T, Guasch G.Socializing with the neighbors: stem cells and their niche[J]. Cell, 2004, 116(6): 769-778.
[27] Ye J, Wu D, Wu P, et al.The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment[J]. Tumour Biol, 2014, 35(5): 3945-3951.
[28] Steeg PS, Bevilacqua G, Kopper L, et al.Evidence for a novel gene associated with low tumor metastatic potential[J]. J Natl Cancer Inst, 1988, 80(3): 200-204.

不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响

Maintenance of the stemness in CD133⁺ primary oral squamous cell carcinoma cells under different culture conditions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谢玉婷, 熊屏. 基于单原子铁纳米催化剂的纳米催化疗法对口腔鳞癌细胞Cal27的作用[J]. 上海口腔医学, 2024, 33(2): 117-122.
[2]	段咏华, 吴开柳, 梅健, 周谊渊, 刘梦石. 口腔鳞癌组织中RACK1与EGP40的表达及其与临床病理特征及预后的相关性[J]. 上海口腔医学, 2023, 32(4): 385-390.
[3]	董淋升, 唐进, 程维, 冉婧璇, 刘兆博, 李雅冬. IL-6和β-catenin在口腔鳞癌中的表达及预后价值[J]. 上海口腔医学, 2023, 32(3): 280-286.
[4]	胡小媛, 王宁, 张晓野, 杨茜, 高菲, 王成勤, 尚伟, 项锋钢, 冯元勇. Chemerin对口腔鳞癌中性粒细胞浸润的影响及机制探讨[J]. 上海口腔医学, 2023, 32(2): 158-165.
[5]	郭梦瑶, 李凯玉, 聂敏海, 刘旭倩. 上调Decorin对口腔鳞癌荷瘤裸鼠EGFR、C-Myc、p21表达的影响[J]. 上海口腔医学, 2023, 32(1): 40-46.
[6]	秦志明, 揭伟萍, 池彦廷, 李宏锋, 李斌斌. 基于局部可变阈值的无监督定量Ki-67细胞增殖指数模型的初步建立[J]. 上海口腔医学, 2022, 31(3): 248-254.
[7]	买尔哈巴·买合木提, 拜婕, 如斯坦木·依米提, 姚志涛. 50例口腔鳞癌患者治疗过程中营养状况改变及影响因素分析[J]. 上海口腔医学, 2022, 31(2): 205-210.
[8]	谈亦然, 赵铜超, 琚梧桐, 钟来平. 长春新碱对口腔鳞癌中Stathmin调控作用的实验研究[J]. 上海口腔医学, 2022, 31(1): 1-5.
[9]	谢非, 秦星, 童桐, 蒋英英, 张建军. IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨[J]. 上海口腔医学, 2021, 30(5): 456-461.
[10]	李蕾, 李晓东, 庄乾伟, 葛良玉, 李志萍, 顾倩平, 白玉婷, 孟箭. 超声热疗联合TPF化疗治疗19例老年晚期口腔鳞癌的疗效分析[J]. 上海口腔医学, 2021, 30(5): 543-547.
[11]	邵小钧, 朱乔, 刘有, 韩小东, 林小臻, 席庆. 咀嚼槟榔与口腔鳞癌的相关临床病理学因素分析[J]. 上海口腔医学, 2021, 30(3): 268-272.
[12]	薛佳艺, 朱晓燕, 危常磊, 孙培, 张慧, 邓婧. 25例口腔鳞癌患者唾液代谢组学分析[J]. 上海口腔医学, 2021, 30(2): 201-205.
[13]	王树斌, 秦帅华, 易雅群, 李新明. 216例口腔鳞癌患者术后心理困扰影响因素及放疗前、后生存质量评价[J]. 上海口腔医学, 2021, 30(1): 71-76.
[14]	傅宗云, 陶峰. MMP-14、ING4和HIF-1α在60例口腔鳞癌中的表达及临床意义[J]. 上海口腔医学, 2020, 29(6): 642-646.
[15]	王学梅, 蒋勇. 双硫仑对口腔鳞癌细胞上皮-间充质转化的影响及机制探讨[J]. 上海口腔医学, 2020, 29(2): 138-145.

不同培养条件对CD133+原代口腔鳞癌细胞干性维持的影响

Maintenance of the stemness in CD133+ primary oral squamous cell carcinoma cells under different culture conditions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响

Maintenance of the stemness in CD133⁺ primary oral squamous cell carcinoma cells under different culture conditions